RSV Burden in Hong Kong

ConditionRSV

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorChinese University of Hong Kong

About this trial

RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Community-acquired respiratory tract infection symptoms

Age >= 18

Disqualifiers

Unable to provide a good quality of sputum and saliva

Trial population

Patients hospitalized for community-acquired respiratory tract infection symptoms

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Serial specimen sampling
Diagnostic test
Serial sampling of nasopharyngeal swab, saliva and sputum for RSV on day 3, 5, 7, 14, 28 (during hospitalization) for patients confirmed with RSV infection. Blood taking will be arranged on day 28 for serology purpose

Treatment groups

10,000 Participants

are divided into 2 treatment groups

Group A: RSV group1 intervention

Group B: Control group0 interventions

Trial outcomes

Primary outcomes

Incidence of RSV infection

The incidence of RSV infection based on the RSV detection rate in respiratory specimens collected from patients with respiratory tract infection symptoms

Time frame

1 month

Secondary outcomes

Incidence of severe RSV infection

The incidence rate of severe RSV infection among patients with respiratory tract infection symptoms, as defined by NIV use, intensive care unit admission, or death

Time frame

1 month

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese University of Hong Kong

Lead sponsor

Source ClinicalTrials.gov

Apply now